Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Expands RNAi Collaboration with U Mass Med School

NEW YORK, April 30 - CytRx of Los Angeles said today that it has expanded its collaboration with University of Massachusetts Medical School, signing an sponsored-research agreement as the first phases of a drug-development effort in obesity and type II diabetes.

 

Michael Czech, chairman of the molecular medicine, will head the research effort that will apply RNAi-directed gene silencing to fat cells for target validation.

 

In early April, CytRx announced that it had signed a license agreement with UMMS for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.

 

Interested in more on RNAi? Read GenomeWeb's weekly roundup of activity.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.